on ALT5 Sigma Corp
ALT5 Sigma Unveils 2024 AGM Results and Strategic Spin-off Plans
ALT5 Sigma Corporation announced the approval of all resolutions at its 2024 Annual General Meeting. The fintech firm, noted for its blockchain-driven solutions, witnessed the re-election of major board members and the election of CEO Peter Tassiopoulos to the board. ALT5 Sigma highlighted its record transaction volumes for 2024, driven in part by growth in its ALT5 Pay and ALT5 Prime platforms.
The company plans to spin off its healthcare assets into Alyea Therapeutics Corporation in 2025. Alyea's independent focus will enhance its strategic capabilities in developing non-addictive pain management solutions. Alyea intends to acquire Soin Bioscience LLC, strengthening its position in the pain relief market.
Vay Tham, ALT5’s Chief Revenue Officer, emphasized continued innovation and expansion in fintech services, anticipating further success in 2025. Discussions on private financing for Alyea are ongoing to address the financial strategy for the spin-off.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ALT5 Sigma Corp news